Glycotest IP strategy is to enable multiple layers of protection for key liver disease tests through multiple patent families prosecuted in commercially important jurisdictions—individual biomarkers; assay technology; panels and algorithms

• HCC Panel patent application (PCT/US2017/018040 and Taiwan 106106107)

o Panels and algorithms, including the HCC Panel

o Issued US (11,408,888), European (3419646), Japanese (7026390), Taiwan (I769149), Mexican (398169) and allowed Chinese patents

•  PCT/US2010/044307

o Engineered lectins and methods for fucosylated biomarker assays

o Issued European (2462240) and Chinese (ZL201080044720.8) patents

•  PCT/US2006/017478

o Methods for diagnosing liver disease using fucosylated biomarkers

o Issued US (7,776,550; 8,183,000; 10,082,512; 10,823,740), European (3056905; 3578985), Australian (2006244398; 2012247075; 2015275300), Japanese (5964769; 6184935; 6553142), Canadian (2607285; 3021449), and Hong Kong (HK1228005; HK40017435) patents

•  US2009/0253180

o Methods for diagnosing liver disease using fucosylated LRAGG

o Issued US patents (9,110,078; 10,180,436)

•  Trade Secrets

o Fucosylated biomarker assay manufacturing technology

o Fucosylated biomarker assay methods